Lupin Receives Approval from U.S. FDA for Pirfenidone Capsules

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pirfenidone Capsules, 267 mg, to market a generic equivalent of Esbriet® Capsules, 267 mg of Hoffmann La Roche Inc. This product will be manufactured at Lupin's Pithampur facility in India.

Pirfenidone Capsules (RLD Esbriet®) had estimated annual sales of USD 95 million in the U.S. (IQVIA MAT June 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1097.05 as compared to the previous close of Rs. 1108.25. The total number of shares traded during the day was 54123 in over 2656 trades.

The stock hit an intraday high of Rs. 1119.95 and intraday low of 1090.30. The net turnover during the day was Rs. 59712884.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDA Approval PirfenidoneCapsules